Skip to main contentSkip to navigationSkip to search

Publications

Advancing scientific exchange 

Discover Camurus’ publications and engagement at conducted and upcoming international medical conferences and events.

Impact of baseline factors on opioid negative urine tests among patients with opioid use disorder receiving weekly/monthly extended-release injectable buprenorphine (CAM2038) vs daily sublingual buprenorphine/naloxone

Comer S.D. et al.

CPDD 2025

Poster

Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial

Lofwall M, et al.

J Addict Med, 2025. Online ahead of print.

Article

Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder

Montgomery C, et al.

BMJ Open, 2025. 15:e090736

Article

Characterizing withdrawal from long-acting injectable buprenorphine: an observational case series

Hayes V, et al.

Drug Alcohol Depend Rep, 2025. 15:100329.

Article

Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings

White B. et al.

Drug Alcohol Rev, 2025. 44(2): 640–648.

Article

Exploring Opioid Use Disorder Outcomes by Quantitative Urine Analysis: Post-hoc Analysis of a Phase 3 Randomised Clinical Trial Comparing a Subcutaneous Buprenorphine Depot (CAM2038) and Sublingual Buprenorphine

Peterson S. et al

EUROPAD 2024

Poster

Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use

Nunes EV, et al.

JAMA Netw Open, 2024. 7(6):e2417377.

Article

Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder

Walsh SL, et al.

Neuropsychopharmacology, 2024. 49(6):1050-1057.

Article

Dosing to Effect with Subcutaneous and Sublingual Buprenorphine for Opioid Use Disorder

Lofwall M. et al.

ASAM 2024

Poster
Show more